L'ORÉAL: News Release: "L'Oréal signs agreement with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
165
L'ORÉAL: News Release: "L'Oréal signs agreement with Valeant to acquire CeraVe and two other brands"

L'ORÉAL SIGNS AGREEMENT WITH VALEANT TO ACQUIRE

CERAVE AND TWO OTHER BRANDS

            Clichy, New York - 10 January 2017 - L'Oréal announced today the signing of a definitive agreement with Valeant to acquire the skincare brands CeraVe, AcneFree and Ambi for a cash purchase price of 1.3 billion US dollars.

CeraVe was founded in 2005 and offers a range of advanced skincare products, specifically cleansers, moisturizers, sunscreens, healing ointments and a dedicated baby line. Developed with dermatologists, CeraVe is one of the fastest growing skincare brands in the U.S. with average growth over the past two years exceeding 20%. CeraVe's multi-channel distribution strategy includes drug stores, mass and beauty retailers, and select online outlets.

AcneFree markets and distributes a full range of OTC cleansers and acne treatments in the U.S., Ambi distributes skincare products formulated for the needs of multicultural consumers. Both brands are distributed in drug stores, mass retailers and select online outlets.

The three brands have annualized combined revenue of approximately 168 million US dollars.

"The acquisition of CeraVe, AcneFree and Ambi strongly complement L'Oréal's brand portfolio," said Frédéric Rozé, President and CEO of L'Oréal USA . "These three brands, built on strong relationships with health professionals and widely distributed, will nearly double the revenue of our Active Cosmetics Division in the US and will help us satisfy the growing demand for active skincare at accessible prices."

CeraVe, AcneFree and Ambi will become part of L'Oréal's Active Cosmetics Division, which includes brands such as La Roche-Posay, Vichy and SkinCeuticals that are developed with and endorsed by health professionals - dermatologists, pediatricians and other physicians.

"We are thrilled to add CeraVe, AcneFree and Ambi to L'Oréal's Active Cosmetics Division. These brands will deepen our relationships with health professionals and will strengthen our positions in North America in this key and fast growing market. Furthermore, we believe CeraVe has a great potential for international growth in the years to come" said Brigitte Liberman, President of L'Oréal Active Cosmetics Division.                                                                                                                                                             The closing is subject to the standard regulatory approvals and other customary conditions.

About L'Oréal L'Oréal has devoted itself to beauty for over 105 years. With its unique international portfolio of 32 diverse and complementary brands, the Group generated sales amounting to 25.26 billion euros in 2015 and employs 82,900 people worldwide. As the world's leading beauty company, L'Oréal is present across all distribution networks: mass market, department stores, pharmacies and drugstores, hair salons, travel retail, branded retail and e-commerce. Research and innovation, and a dedicated research team of 3,870 people, are at the core of L'Oréal's strategy, working to meet beauty aspirations all over the world. L'Oréal's sustainability commitment for 2020 "Sharing Beauty With All" sets out ambitious sustainable development objectives across the Group's value chain. www.loreal.com

"This news release does not constitute an offer to sell, or a solicitation of an offer to buy L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers, also available in English on our Internet site www.loreal-finance.com . This news release may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."

Contacts at L'Oréal (switchboard: +33 1 47 56 70 00)

Individual shareholders and market authorities Mr Jean Régis CAROF Tel: +33 1 47 56 83 02 jean-regis.carof@loreal.com  

Financial analysts and Institutional investors Mrs Françoise LAUVIN Tel: +33 1 47 56 86 82 francoise.lauvin@loreal.com

Journalists   Mrs Anne-Laure RICHARD Tel: +33 1 47 56 80 68 annelaure.richard@loreal.com

For more information, please contact your bank, broker or financial institution (I.S.I.N. code: FR0000120321), and consult your usual newspapers, the Internet site for shareholders and investors, www.loreal-finance.com or the L'Oréal Finance app, alternatively, call +33 1 40 14 80 50.

www.loreal.com - Follow us on Twitter @Loreal

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...7f70f6adb2

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 13

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 243

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 139

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 11

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 464

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 39

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 82

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 43

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading

Top 5 Most Recently Viewed Articles

Topicus.com Reports Q3 2025 Financial Results with Growth

Updated Category News Views 757

Financial Overview of Topicus.com Inc. for Q3 2025 In a significant financial announcement, Topicus.com Inc. (TSXV: TOI), in conjunction with Constellation Software Inc. (TSX: CSU), has shared their results for the third quarter of 2025. For the quarter ending on September 30, 2025, the total revenue reached €387.9 million, which reveals an impressive 24% increase from...

Continue Reading
First Financial Security, Inc. Executes a Strategic 10-for-1 Stock Split

Updated Category News Views 266

Strategic 10-for-1 Stock Split Announcement by First Financial Security, Inc. First Financial Security, Inc. (FFS) has recently announced a significant corporate action — a 10-for-1 stock split of its authorized shares of common stock. This adjustment is a clear indication of the company’s positive growth outlook and its unwavering commitment to providing enhanced...

Continue Reading
Octopus AIM VCT plc Reports Strong Net Asset Value Update

Updated Category News Views 55

Overview of Octopus AIM VCT plc Octopus AIM VCT plc is a distinguished investment firm known for its focus on investments in AIM-listed companies. The firm aims to provide investors with significant returns through its carefully managed portfolio, making it a key player in the investment landscape. With a commitment to transparency and value, Octopus AIM VCT plc regularly...

Continue Reading
Revolt CBD Shows Innovation and Growth in Its Latest Update

Updated Category News Views 180

Revolt CBD Launches Innovative Website Redesign In a significant move towards enhancing customer engagement, Revolt CBD has officially unveiled its newly redesigned website. This development marks a pivotal moment for the brand as it strives to improve accessibility, transparency, and innovation in 2026. The new online platform is designed to better reflect the brand's...

Continue Reading
Strategic Merger to Enhance Biopharmaceutical Innovations

Updated Category News Views 86

Exciting Merger Between ACELYRIN and Alumis The proposed merger between ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. marks a pivotal moment in the biopharma landscape focused on immune-mediated diseases. This partnership is set to create a robust clinical stage company, combining strengths and resources to deliver transformative treatment options to patients. Key...

Continue Reading